Aldeyra Income Tax Expense Over Time

ALDX Stock  USD 4.85  0.04  0.83%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aldeyra Performance and Aldeyra Correlation.
For more information on how to buy Aldeyra Stock please use our How to Invest in Aldeyra guide.
  
Income Tax Expense is likely to drop to about (791.3 K) in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aldeyra. If investors know Aldeyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aldeyra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.75)
Return On Assets
(0.23)
Return On Equity
(0.43)
The market value of Aldeyra is measured differently than its book value, which is the value of Aldeyra that is recorded on the company's balance sheet. Investors also form their own opinion of Aldeyra's value that differs from its market value or its book value, called intrinsic value, which is Aldeyra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aldeyra's market value can be influenced by many factors that don't directly affect Aldeyra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aldeyra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aldeyra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aldeyra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Income Tax Expense Analysis

Compare Aldeyra and related stocks such as Tarsus Pharmaceuticals, LianBio ADR, and Travere Therapeutics Income Tax Expense Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
TARS1000100010001000100010001000100010001000100055 K(4 K)709.1 K744.6 K
TVTX(23 K)2.8 K2.8 K75.8 K(2.5 M)(11.8 M)(9.7 M)1.4 M811 K(21 K)(19.4 M)409 K313 K223 K234.2 K
ETON0.00.00.00.00.00.00.00.0(2.6 M)(281 K)859 KM761 K247 K259.4 K
VRDN3.2 M3.2 M3.2 MMM95 K95 K95 K1.3 M547 K269 KK(4.4 M)18.6 M19.5 M
TERN(67 K)(67 K)(67 K)(67 K)(67 K)(67 K)(67 K)(67 K)(67 K)(20 K)813 K508 K358 K239 K335.7 K
GPCR13813813813813813813813813813813823117 K236 K247.8 K
BPMC364 K364 K364 K364 K355 K(681 K)(562 K)M10.5 M(19 M)1.1 MM5.2 M968 KM
ETNB28 K28 K28 K28 K28 K28 K28 K28 K28 K218 K(59 K)(147 K)19 K3.9 M4.1 M
XFOR395 K395 K395 K395 K395 K395 K2.6 M1.9 M3.9 M3.8 M148 K17 K28 K78 K74.1 K
INZY4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M(1.1 M)(587 K)(211 K)(1.6 M)(1.5 M)(1.4 M)
DAWN(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(2.3 M)(3.3 M)(2.3 M)(10 M)(9 M)(8.6 M)
HOOKKKKKKKKK24 K(8.9 M)(10.3 M)1000230 K368 K386.4 K
PHAT13 K13 K13 K13 K13 K13 K13 K13 K13 K(45.4 M)4.2 M4.2 M25.3 M41.8 M43.9 M
LYRA(1.2 M)(1.2 M)(1.2 M)(1.2 M)(1.2 M)(1.2 M)(1.2 M)(1.2 M)(1.2 M)(213 K)(82 K)(1.1 M)13 K59 K62 K
CGEM0.00.00.00.00.00.00.0397 K397 K(1.6 M)(8.6 M)(2.4 M)42.1 M(14.1 M)(13.4 M)
BLRX1.6 M(2.2 M)(1.4 M)15.8 K(5.7 M)(1.8 M)(672 K)(888 K)(4.5 M)1.4 M911 K1.1 M(6.1 M)10001.1 K
ARDX950 K950 K950 K141 K67 K(29 K)29 K1.2 MK303 KKKK547 K574.4 K
LXRX(300 K)(2.4 M)(2 M)(833 K)(70 K)M4.5 M(12.7 M)3.5 M(6 M)11.6 M510 K1.2 M386.1 K405.4 K
MCRB42 K42 K42 K42 K1.6 M(804 K)2.2 M(1.6 M)1.3 M(6 M)(2.7 M)(4.1 M)3.7 M14.9 M15.7 M
IBRX10001000100010001000(301 K)(572 K)(493 K)(503 K)(105 K)(1.8 M)K34 K(40 K)(42 K)

Aldeyra and related stocks such as Tarsus Pharmaceuticals, LianBio ADR, and Travere Therapeutics Income Tax Expense description

My Equities

My Current Equities and Potential Positions

Aldeyra
ALDX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 4.85

Additional Tools for Aldeyra Stock Analysis

When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.